DFDiogo Ferreira

Diogo Ferreira

*This is an algorithmically generated author record based on publicly available information.

Diogo Ferreira has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Catarina Rocha

    1 shared publication
  • Ana Cláudia Pereira

    RISE-Health,School of Medicine and Biomedical Sciences, Fernando Pessoa University, Fernando Pessoa Teaching and Culture Foundation, Avenida Fernando Pessoa 150, 4420-096,Gondomar,Portugal; FP-I3ID—Instituto de Investigação, Inovação e De-senvolvimentoFernando Pessoa-Biomedical Health Sciences (FPBHS), University Fernando Pessoa, Praça de 9 de Abril 349, 4249-004,Porto,Portugal, Portugal

    1 shared publication
  • André P. Sousa

    FP-I3ID, FP-BHS, Instituto de Investigação, Inovação e Desenvolvimento, Biomedical Health Sciences, Universidade Fernando Pessoa (UFP), 4249-004 Porto, Portugal

    1 shared publication
  • Carla Luís

    Universidade Fernando Pessoa, Porto, Portugal

    1 shared publication
  • Daniela Martins-Mendes

    RISE-Health,School of Medicine and Biomedical Sciences, Fernando Pessoa University, Fernando Pessoa Teaching and Culture Foundation, Avenida Fernando Pessoa 150, 4420-096,Gondomar,Portugal; FP-I3ID—Instituto de Investigação, Inovação e De-senvolvimento,Fernando Pessoa-Biomedical Health Sciences (FPBHS), University Fernando Pessoa, Praça de 9 de Abril 349, 4249-004,Porto,Portugal, Portugal

    1 shared publication
  • Joana Rigor

    1 shared publication

Latest Publications

  • Open Access

    Exploring the Leading Hypotheses of the Prostate Cancer Paradox: Cytological and Genetic Implications

    by André P Sousa, Ana Catarina Rocha, Ana Cláudia Pereira, Carla Luís, Joana Rigor, Diogo Ferreira, Daniela Martins-Mendes, Pilar Baylina, Raquel Soares, Fernanda Duarte, et al.

    Type 2 diabetes mellitus (T2DM) is associated with a tumor-promoting metabolic environment, yet epidemiological evidence suggests an inverse association with prostate cancer (PCa), giving rise to the PCa–T2DM paradox. We investigated whether major proposed mechanisms could reproduce the effects of plasma from patients with T2DM in prostate cell models. PC3, LNCaP, and HPEpiC cells were exposed to 10% plasma from 16 patients with T2DM for 24 h. Antidiabetic drugs, testosterone and estradiol, glucose, and methylglyoxal were then evaluated independently. Patient-derived plasma markedly reduced viability to 29.0 ± 3.9% in PC3, 67.4 ± 13.6% in LNCaP, and 53.1 ± 2.0% in HPEpiC cells. None of the tested antidiabetic drugs reproduced this response at clinically relevant concentrations. Hormonal modulation altered macrophage polarization and prostate-cell viability but produced only selective, cell-dependent effects. Increasing glucose concentrations enhanced viability in PC3 and LNCaP cells, whereas methylglyoxal reduced viability only in HPEpiC cells at the highest concentrations tested. Overall, none of the major isolated pharmacological, hormonal, glycemic, or glycation-related mechanisms reproduced the plasma-associated phenotype, suggesting that it may arise from the integrated influence of multiple circulating components and signaling pathways.